Skip to main content
AAN.com
Editorials
December 17, 2014

Does migraine produce facial palsy?
For whom the Bell tolls

January 13, 2015 issue
84 (2) 108-109

Abstract

Bell palsy (also known as Bell's palsy) is an acute, ipsilateral, facial nerve paralysis of unknown etiology that results in weakness of the platysma and muscles of facial expression.1 Bell palsy affects 11 to 40 persons per 100,000 each year, with peak incidence between the ages of 15 and 50 years and both sexes are affected equally. Pregnant women, persons with diabetes, the elderly, and patients with hypothyroidism are at increased risk.2

Get full access to this article

View all available purchase options and get full access to this article.

REFERENCES

1.
Gilden DH. Clinical practice: Bell's palsy. N Engl J Med 2004;351:1323–1331.
2.
Zandian A, Osiro S, Hudson R, et al. The neurologist's dilemma: a comprehensive clinical review of Bell's palsy, with emphasis on current management trends. Med Sci Monit 2014;20:83–90.
3.
Jensen R, Stovner LJ. Epidemiology and comorbidity of headache. Lancet Neurol 2008;7:354–361.
4.
Zachariah J, Patel P. Facial pain with recurrent facial palsy. Headache 2003;43:700–701.
5.
Russell MB, Ducros A. Sporadic and familial hemiplegic migraine: pathophysiological mechanisms, clinical characteristics, diagnosis, and management. Lancet Neurol 2011;10:457–470.
6.
Peng KP, Chen YT, Fuh JL, Tang CH, Wang SJ. Increased risk of Bell palsy in patients with migraine: a nationwide cohort study. Neurology 2015;84:116–124.
7.
Jorg R, Milani GP, Simonetti GD, Bianchetti MG, Simonetti BG. Peripheral facial nerve palsy in severe systemic hypertension: a systematic review. Am J Hypertens 2013;26:351–356.
8.
Adour K, Wingerd J, Doty HE. Prevalence of concurrent diabetes mellitus and idiopathic facial paralysis (Bell's palsy). Diabetes 1975;24:449–451.
9.
Brandenburg NA, Annegers JF. Incidence and risk factors for Bell's palsy in Laredo, Texas: 1974–1982. Neuroepidemiology 1993;12:313–325.
10.
Morris AM, Deeks SL, Hill MD, et al. Annualized incidence and spectrum of illness from an outbreak investigation of Bell's palsy. Neuroepidemiology 2002;21:255–261.
11.
Monini S, Lazzarino AI, Iacolucci C, Buffoni A, Barbara M. Epidemiology of Bell's palsy in an Italian Health District: incidence and case-control study. Acta Otorhinolaryngol Ital 2010;30:198.

Information & Authors

Information

Published In

Neurology®
Volume 84Number 2January 13, 2015
Pages: 108-109
PubMed: 25520314

Publication History

Published online: December 17, 2014
Published in print: January 13, 2015

Permissions

Request permissions for this article.

Disclosure

Dr. S. Silberstein serves as a consultant and/or advisory board member and receives honoraria from Alder Biopharmaceuticals; Allergan, Inc.; Amgen; Avanir Pharmaceuticals, Inc.; eNeura Inc.; ElectroCore Medical, LLC; Medscape, LLC; Medtronic, Inc.; Mitsubishi Tanabe Pharma America, Inc.; National Institute of Neurological Disorders and Stroke; Pfizer, Inc.; Supernus Pharmaceuticals, Inc.; and Teva Pharmaceuticals. Dr. M. Silvestrini reports no disclosures relevant to the manuscript. Go to Neurology.org for full disclosures.

Authors

Affiliations & Disclosures

Stephen D. Silberstein, MD, FAHS, FACP
From Thomas Jefferson University (S.D.S.), Philadelphia, PA; and Marche Polytechnic University (M.S.), Ancona, Italy.
Disclosure
Scientific Advisory Boards:
1.
(1) Alder, (2) Allergan, (3) Amgen, (3) Avanir,(4)eNeura, (5) ElectroCore Medical, (6) Medscape, (7) Medtronic, (8) Mitsubishi Tanabe, (9) Neuralieve, (10) NINDS, (11) Pfizer, (12) Supernus, (13) Teva
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
(1) Cephalalgia, (2) Current Pain and Headache Reports, (3) CNS Drugs, (4) Topics in Pain Management, (5) Neurology
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
(1) Allergan, (2) Amgen, (3)eNeura, (4) ElectroCore Medical, (5) Mitsubishi Tanabe, (6) Medtronic, (7) Neuralieve, (8) Pfizer, (9) Supernus, (10) Teva
Speakers' Bureaus:
1.
None now; past 2 years: (1) Allergan, (2) Endo Pharmaceuticals, (3)GlaxoSmithKline, (4) Zogenix, (5) Merck
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
Past 2 years: (1) GlaxoSmithKline, (2) Allergan, (3) Merck, (4) Novartis, (5) NIH, (6) Neurolieve, (7) MAP, (8) Endo Now: Amgen, ElectroCore
Research Support, Government Entities:
1.
(1) NIH
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
(1) AHS, (2) IHS
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Mauro Silvestrini, MD
From Thomas Jefferson University (S.D.S.), Philadelphia, PA; and Marche Polytechnic University (M.S.), Ancona, Italy.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
Journal of Alzheimer's Disease, Associate Editor, 2012, 2013, 2014
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE

Notes

Correspondence to Dr. Silberstein: [email protected]
Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the editorial.

Metrics & Citations

Metrics

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. Acute Management of Bell’s Palsy, Current Otorhinolaryngology Reports, 6, 2, (161-170), (2018).https://doi.org/10.1007/s40136-018-0198-0
    Crossref
Loading...

View Options

Get Access

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

Purchase this article to get full access to it.

Purchase Access, $39 for 24hr of access

View options

Full Text

View Full Text

Full Text HTML

View Full Text HTML

Media

Figures

Other

Tables

Share

Share

Share article link

Share